Stockwatch: An oasis of lipid-lowering therapies and a desert of reimbursement
This article was originally published in Scrip
Last week was chock-full of commentary from the FDA Advisory Panels on the new lipid-lowering drugs directed against PCSK9 from Amgen and Sanofi/Regeneron Pharmaceuticals. Amongst those and other related companies, the only share price winner of the week was Sanofi, with its main listing outside of the US, and even then it was for the wrong reason.
You may also be interested in...
Oncology diagnoses and therefore revenues are returning as we emerge from the pandemic, but the recovery also brings the challenges of reduced diagnostic and eventually vaccine revenues.
Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.
The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.